Literature DB >> 29123457

Survival benefit of postoperative radiation in papillary meningioma: Analysis of the National Cancer Data Base.

Whitney A Sumner1, Arya Amini1, Todd C Hankinson2, Nicholas K Foreman3, Laurie E Gaspar1, Brian D Kavanagh1, Sana D Karam1, Chad G Rusthoven1, Arthur K Liu1.   

Abstract

AIM/
BACKGROUND: Papillary meningioma represents a rare subset of World Health Organization (WHO) Grade III meningioma that portends an overall poor prognosis. There is relatively limited data regarding the benefit of postoperative radiation therapy (PORT). We used the National Cancer Data Base (NCDB) to compare overall survival (OS) outcomes of surgically resected papillary meningioma cases undergoing PORT compared to post-operative observation.
MATERIALS AND METHODS: The NCDB was queried for patients with papillary meningioma, diagnosed between 2004 and 2013, who underwent upfront surgery with or without PORT. Overall survival (OS) was determined using the Kaplan-Meier method. Univariate (UVA) and multivariate (MVA) analyses were performed.
RESULTS: In total, 190 patients were identified; 89 patients underwent PORT, 101 patients were observed. Eleven patients received chemotherapy (6 with PORT, 5 without). 2-Year OS was significantly improved with PORT vs. no PORT (93.0% vs. 74.4%), as was 5-year OS (78.5% vs. 62.5%) (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.27-0.85; p = 0.01). On MVA, patients receiving PORT had improved OS compared to observation (HR, 0.41; 95% CI, 0.22-0.76; p = 0.005). On subset analysis by age group, the benefit of PORT vs. no PORT was significant in patients ≤18 years (n = 13), with 2-year OS of 85.7% vs. 50.0% (HR, 0.08; 95% CI, 0.01-0.80; p = 0.032) and for patients >18 years (n = 184), with 2-year OS of 94.7% vs. 76.1% (HR, 0.55; 95% CI, 0.31-1.00; p = 0.049), respectively.
CONCLUSIONS: In this large contemporary analysis, PORT was associated with improved survival for both adult and pediatric patients with papillary meningioma. PORT should be considered in those who present with this rare, aggressive tumor.

Entities:  

Keywords:  Meningioma; National Cancer Data Base (NCDB); PORT; Postoperative radiation

Year:  2017        PMID: 29123457      PMCID: PMC5671614          DOI: 10.1016/j.rpor.2017.10.001

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  29 in total

1.  Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.

Authors:  S M Grunberg; M H Weiss; I M Spitz; J Ahmadi; A Sadun; C A Russell; L Lucci; L L Stevenson
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

2.  A note on quantifying follow-up in studies of failure time.

Authors:  M Schemper; T L Smith
Journal:  Control Clin Trials       Date:  1996-08

3.  Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.

Authors:  Michael E Sughrue; Nader Sanai; Gopal Shangari; Andrew T Parsa; Mitchel S Berger; Michael W McDermott
Journal:  J Neurosurg       Date:  2010-08       Impact factor: 5.115

4.  Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy.

Authors:  E B Hug; A Devries; A F Thornton; J E Munzenride; F S Pardo; E T Hedley-Whyte; M R Bussiere; R Ojemann
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

5.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

Authors:  U M Schrell; M G Rittig; M Anders; U H Koch; R Marschalek; F Kiesewetter; R Fahlbusch
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

6.  Efficacy of postoperative radiotherapy for high grade meningiomas.

Authors:  Yunseon Choi; Do Hoon Lim; Kyungil Jo; Do-Hyun Nam; Ho Jun Seol; Jung-Il Lee
Journal:  J Neurooncol       Date:  2014-06-26       Impact factor: 4.130

7.  Systematic Analysis of Outcomes for Surgical Resection and Radiotherapy in Patients with Papillary Meningioma.

Authors:  Christina Fong; Daniel T Nagasawa; Lawrance K Chung; Brittany Voth; Nicole Cremer; Kimberly Thill; Nolan Ung; Quinton Gopen; Isaac Yang
Journal:  J Neurol Surg B Skull Base       Date:  2015-03-12

8.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.

Authors:  Peter C Austin
Journal:  Pharm Stat       Date:  2011 Mar-Apr       Impact factor: 1.894

9.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

Review 10.  Radiation Treatment for WHO Grade II and III Meningiomas.

Authors:  Brian P Walcott; Brian V Nahed; Priscilla K Brastianos; Jay S Loeffler
Journal:  Front Oncol       Date:  2013-09-02       Impact factor: 6.244

View more
  5 in total

1.  Papillary meningioma of the central nervous system: a SEER database analysis.

Authors:  Fujun Liu; Yuan Tian; Liangxue Zhou
Journal:  Neurosurg Rev       Date:  2021-01-08       Impact factor: 3.042

2.  Initial management of meningiomas: Analysis of the National Cancer Database.

Authors:  Catherine R Garcia; Stacey A Slone; Monica Chau; Janna H Neltner; Thomas Pittman; John L Villano
Journal:  Cancer Epidemiol       Date:  2019-03-14       Impact factor: 2.984

Review 3.  Adjuvant radiotherapy and stereotactic radiosurgery in grade 3 meningiomas - a systematic review and meta-analysis.

Authors:  Amon Bergner; Andrea Daniela Maier; Christian Mirian; Tiit Illimar Mathiesen
Journal:  Neurosurg Rev       Date:  2022-05-11       Impact factor: 2.800

Review 4.  Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review.

Authors:  P D Delgado-López; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2020-07-10       Impact factor: 3.405

Review 5.  Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues.

Authors:  Lorenzo Vagnoni; Sami Aburas; Martina Giraffa; Ivana Russo; Vito Chiarella; Sergio Paolini; Paolo Tini; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2022-06-04       Impact factor: 2.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.